Emerging drug for diarrhea predominant irritable bowel syndrome

Bibliography

• World Gastroenterology Organization. Irritable bowel syndrome: a global perspective. World gastroenterology organisation global guideline. 2009. Available from: http://www.jupiterpharma.in/journalpdf/IBS WORLD GASTRO.pdf
   Google Scholar
• Drossman DA, Corrazziari E, Delvaux M, et al. Rome III: The functional gastrointestinal disorders. Degnon Associates; McLean, VA: 2006
   Google Scholar
• Drossman DA, Corazziari E, Talley NJ, et al. Rome II: The functional gastrointestinal disorders: diagnosis, pathophysiology, and treatment: a multinational consensus. 2nd edition. Degnon Associates; McLean, VA: 2000
   Google Scholar
• Barbara G, Cremon C, Carini G, et al. The immune system in irritable bowel syndrome. J Neurogastroenterol Motil 2011;17:349-59
   PubMed Web of Science ®Google Scholar
• Quigley EM, Abdel-Hamid H, Barbara G, et al. A global perspective on irritable bowel syndrome: a consensus statement of the World Gastroenterology Organisation Summit Task Force on irritable bowel syndrome. J Clin Gastroenterol 2012;46:356-66
   PubMed Web of Science ®Google Scholar
• Occhipinti K, Smith JW. Irritable bowel syndrome: a review and update. Clin Colon Rectal Surg 2012;25:46-52
   PubMedGoogle Scholar
• Akehurst R, Kaltenthaler E. Treatment of irritable bowel syndrome: a review of randomised controlled trials. Gut 2001;48:272-82
   PubMed Web of Science ®Google Scholar
• Ford AC, Moayyedi P. Meta-analysis: factors affecting placebo response rate in the irritable bowel syndrome. Aliment Pharmacol her 2010;32:144-58
   PubMed Web of Science ®Google Scholar
• Li L, Xiong L, Zhang S, et al. Cognitive-behavioral therapy for irritable bowel syndrome: a meta-analysis. J Psychosom Res 2014;77(1):1-12
   PubMed Web of Science ®Google Scholar
• Brandt LJ, Chey WD, Foxx-Orenstein AE, et al. American college of gastroenterology task force on irritable bowel syndrome. An evidence-based position statement on the management of irritable bowel syndrome. Am J Gastroenterol 2009;104(Suppl 1):S1-35
   PubMed Web of Science ®Google Scholar
• Bijkerk CJ, Muris JW, Knottnerus JA, et al. Systematic review: the role of different types of fibre in the treatment of irritable bowel syndrome. Aliment Pharmacol Ther 2004;19:245-51
   PubMed Web of Science ®Google Scholar
• Ford AC, Talley NJ. Irritable bowel syndrome. BMJ 2012;345:e5836
   PubMedGoogle Scholar
• Heizer WD, Southern S, McGovern S. The role of diet in symptoms of irritable bowel syndrome in adults: a narrative review. J Am Diet Assoc 2009;109:1204-14
   PubMed Web of Science ®Google Scholar
• Daley AJ, Grimmett C, Roberts L, et al. The effects of exercise upon symptoms and quality of life in patients diagnosed with irritable bowel syndrome: a randomised controlled trial. Int J Sports Med 2008;29:778-82
   PubMed Web of Science ®Google Scholar
• Lea R, Whorwell PJ. The role of food intolerance in irritable bowel syndrome. Gastroenterol Clin North Am 2005;34:247-55
   PubMed Web of Science ®Google Scholar
• Saberi-Firoozi M, Khademolhosseini F, Mehrabani D, et al. Subjective lactose intolerance in apparently healthy adults in southern Iran: is it related to irritable bowel syndrome? Indian J Med Sci 2007;61:591-7
   PubMedGoogle Scholar
• Gupta D, Ghoshal UC, Misra A, et al. Lactose intolerance in patients with irritable bowel syndrome from northern India: a case-control study. J Gastroenterol Hepatol 2007;22:2261-5
   PubMed Web of Science ®Google Scholar
• Gibson PR, Shepherd SJ. Evidence-based dietary management of functional gastrointestinal symptoms: the FODMAP approach. J Gastroenterol Hepatol 2010;25:252-8
   PubMed Web of Science ®Google Scholar
• Shepherd SJ, Gibson PR. Fructose malabsorption and symptoms of irritable bowel syndrome: guidelines for effective dietary management. J Am Diet Assoc 2006;106:1631-9
   PubMed Web of Science ®Google Scholar
• Shepherd SJ, Parker FC, Muir JG, et al. Dietary triggers of abdominal symptoms in patients with irritable bowel syndrome: randomized placebo-controlled evidence. Clin Gastroenterol Hepatol 2008;6:765-71
   PubMed Web of Science ®Google Scholar
• Emma P. Halmos, Victoria A, et al. A diet low in FODMAPs reduces symptoms of irritable bowel syndrome. Gastroenterology 2014;146:67-75
   PubMed Web of Science ®Google Scholar
• Ford AC, Talley NJ, Schoenfeld PS, et al. Efficacy of antidepressants and psychological therapies in irritable bowel syndrome: systematic review and meta-analysis. Gut 2009;58:367-78
   PubMed Web of Science ®Google Scholar
• Lindfors P, Unge P, Arvidsson P, et al. Effects of gut-directed hypnotherapyon IBS in different clinical settings-results from two randomized, controlled trials. Am J Gastroenterol 2012;107:276-85
   PubMed Web of Science ®Google Scholar
• Lowén MB, Mayer EA, Sjöberg M, et al. Effect of hypnotherapy and educational intervention on brain response to visceral stimulus in the irritable bowel syndrome. Aliment Pharmacol Ther 2013;37:1184-97
   PubMed Web of Science ®Google Scholar
• Spiller R, Aziz Q, Creed F, et al. Clinical services committee of the british society of gastroenterology. guidelines on the irritable bowel syndrome: mechanisms and practical management. Gut 2007;56:1770-98
   PubMed Web of Science ®Google Scholar
• Brandt LJ, Chey WD, Foxx-Orenstein AE, et al. American college of gastroenterology task force on irritable bowel syndrome. An evidence-based position statement on the management of irritable bowel syndrome. Am J Gastroenterol 2009;104(Suppl 1):S1-35
   PubMed Web of Science ®Google Scholar
• Lavö B, Stenstam M, Nielsen AL. Loperamide in treatment of irritable bowel syndrome--a double-blind placebo controlled study. Scand J Gastroenterol Suppl 1987;130:77-80
   PubMedGoogle Scholar
• Cann PA, Read NW, Holdsworth CD, Barends D. Role of loperamide and placebo in management of irritable bowel syndrome (IBS). Dig Dis Sci 1984;29:239-47
   PubMed Web of Science ®Google Scholar
• Efskind PS, Bernklev T, Vatn MH. A double blind placebo-controlled trial with loperamide in irritable bowel syndrome. Scand J Gastroenterol 1996;31:463-8
   PubMed Web of Science ®Google Scholar
• Loperamide. Package Insert. Janssen Pharmaceutica, Inc. 1998. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2005/017694s050lbl.pdf [Last accessed 4 June 2014]
   Google Scholar
• Brunton L, Chabner B, Knollman B, et al. Goodman & gilman’s the pharmacological basis of therapeutics. 12th Edition. McGraw-Hill Companies; 2012
   Google Scholar
• Rang HP, Dale MM, Ritter JM, et al. Rang and Dale’s pharmacology. 7th edition. Elselvier; 2012
   Google Scholar
• Tan-No K, Niijima F, Nakagawasai O, et al. Development of tolerance to the inhibitory effect of loperamide on gastrointestinal transit in mice. Eur J Pharm Sci 2003;20(3):357-63
   PubMed Web of Science ®Google Scholar
• Tack J, Fried M, Houghton LA, et al. Systematic review: the efficacy of treatments for irritable bowel syndrome-a European perspective. Aliment Pharmacol Ther 2006;24:183-205
   PubMed Web of Science ®Google Scholar
• Garsed K, Chernova J, Hastings M, et al. A randomised trial of ondansetron for the treatment of irritable bowel syndrome with diarrhea. Gut 2014;63(10):1617-25
   PubMed Web of Science ®Google Scholar
• US Food and Drug Administration (FDA). Lotronex (alosetron hydrochloride) information. FDA website [online] 2012
   Google Scholar
• US Food and Drug Administration (FDA). Questions and answers about lotronex. FDA website [online] 2013
   Google Scholar
• Chang L, Chey WD, Harris L, et al. Incidence of ischemic colitis and serious complications of constipation among patients using alosetron: systematic review of clinical trials and post-marketing surveillance data. Am J Gastroenterol 2006;101:1069-79
   PubMed Web of Science ®Google Scholar
• Eichler HG, Bloechl-Daum B, Brasseur D, et al. The risks of risk version in drug regulation. Nat Rev Drug Discov 2013;12:907-16
   PubMed Web of Science ®Google Scholar
• Wedlake L, A’Hern R, Russell D, et al. Systematic review: the prevalence of idiopathic bile acid malabsorption as diagnosed by SeHCAT scanning in patients with diarrhoea-predominant irritable bowel syndrome. Aliment Pharmacol Ther 2009;30:707-17
   PubMed Web of Science ®Google Scholar
• Corinaldesi R, Stanghellini V, Cremon C, et al. Effect of mesalazine on mucosal immune biomarkers in irritable bowel syndrome: a randomized controlled proof-of-concept study. Aliment Pharmacol Ther 2009;30(3):245-52
   PubMed Web of Science ®Google Scholar
• Andrews CN, Griffiths TA, Kaufman J, et al. Mesalazine (5-aminosalicylic acid) alters faecal bacterial profiles, but not mucosal proteolytic activity in diarrhoea-predominant irritable bowel syndrome. Aliment Pharmacol Ther 2011;34(3):374-83
   PubMed Web of Science ®Google Scholar
• Bafutto M, Almeida JR, Leite NV, et al. Treatment of postinfectious irritable bowel syndrome and noninfective irritable bowel syndrome with mesalazine. Arq Gastroenterol 2011;48:36-40
   PubMedGoogle Scholar
• Pimentel M, Lembo A, Chey WD, et al. TARGET Study Group. Rifaximin therapy for patients with irritable bowel syndrome without constipation. N Engl J Med 2011;364(1):22-32
   PubMed Web of Science ®Google Scholar
• Schoenfeld P, Pimentel M, Chang L, et al. Safety and tolerability of rifaximin for the treatment of irritable bowel syndrome without constipation: a pooled analysis of randomised, double-blind, placebo-controlled trials. Aliment Pharmacol Ther 2014;39(10):1161-8
   PubMed Web of Science ®Google Scholar
• Food and Drug Administration. Xifaxan (rifaximin) tablets, 550 µg NDA 21-361: briefing document for gastrointestinal drugs advisory committee meeting. 2011. Available from: http://www.fda.gov/downloads/advisorycommittees/committeesmeetingmaterials/drugs/gastrointestinaldrugsadvisorycommittee/ucm279646.pdf [Last accessed 27 September 2013]
   Google Scholar
• Schey R, Rao SS. The role of rifaximin therapy in patients with irritable bowel syndrome without constipation. Expert Rev Gastroenterol Hepatol 2011;5(4):461-4
   PubMed Web of Science ®Google Scholar
• Cremonini F, Lembo A. Rifaximin for the treatment of irritable bowel syndrome. Expert Opin Pharmacother 2012;13(3):433-40
   PubMed Web of Science ®Google Scholar
• Rivkin A, Gim S. Rifaximin: new therapeutic indication and future directions. Clin Ther 2011;33(7):812-27
   PubMed Web of Science ®Google Scholar
• Pimentel M, Park S, Mirocha J, et al. The effect of a nonabsorbed oral antibiotic (rifaximin) on the symptoms of the irritable bowel syndrome: a randomized trial. Ann Intern Med 2006;145(8):557-63
   PubMed Web of Science ®Google Scholar
• Moayyedi P, Ford AC, Talley NJ, et al. The efficacy of probiotics in the treatment of irritable bowel syndrome: a systematic review. Gut 2010;59:325-32
   PubMed Web of Science ®Google Scholar
• Whorwell PJ, Altringer L, Morel J, et al. Efficacy of an encapsulated probiotic Bifidobacterium infantis 35624 in women with irritable bowel syndrome. Am J Gastroenterol 2006;101(7):1581-90
   PubMed Web of Science ®Google Scholar
• Bellini M, Gemignani A, Gambaccini D, et al. Evaluation of latent links between irritable bowel syndrome and sleep quality. World J Gastroenterol 2011;17:5089-96
   PubMed Web of Science ®Google Scholar
• Drossman DA, Camilleri M, Mayer EA, et al. AGA technical review on irritable bowel syndrome. Gastroenterology 2002;123:2108-31
   PubMed Web of Science ®Google Scholar
• Moayyedi P, Ford AC, Talley NJ, et al. The efficacy of probiotics in the treatment of irritable bowel syndrome: a systematic review. Gut 2010;59:325-32
   PubMed Web of Science ®Google Scholar
• Sandler RS, Everhart JE, Donowitz M, et al. The burden of selected digestive diseases in the United States. Gastroenterology 2002;122:1500-11
   PubMed Web of Science ®Google Scholar
• El-Serag HB, Olden K, Bjorkman D. Health-related quality of life among persons with irritable bowel syndrome: a systematic review. Aliment Pharmacol Ther 2002;16:1171-85
   PubMed Web of Science ®Google Scholar
• Camilleri M, Williams DE. Economic burden of irritable bowel syndrome. Proposed strategies to control expenditures. Pharmacoeconomics 2000;17(4):331-8
   PubMed Web of Science ®Google Scholar
• Inadomi JM, Fennerty MB, Bjorkman D. The economic impact of irritable bowel syndrome. Aliment Pharmacol Ther 2003;18(7):671-82
   PubMed Web of Science ®Google Scholar
• Levy RL, Linde JA, Feld KA, et al. The association of gastrointestinal symptoms with weight,diet, and exercise in weight-loss program participants. Clin Gastroenterol Hepatol 2005;3:992-6
   PubMed Web of Science ®Google Scholar
• Tack JF, Miner PB, Fischer L, et al. Randomised clinical trial: the safety and efficacy of AST-120 in non-constipating irritable bowel syndrome – a double-blind, placebocontrolled study. Aliment Pharmacol Ther 2011;43:868-77
   Google Scholar
• Anderson K, Tomiyana S, Nitta T. AST120: a novel, engineeered carbon microsphere product for use in chronic inflammatory bowel disease and liver dysfunction. Gastroenterology 2008;134(Suppl 1):A675
   Google Scholar
• Wilmer J, Anderson K, Proksch S, et al. Absence of pharmacokinetic drug-drug interactions in healthy volunteers between AST-120, a novel oral adsorbent and concomitant medications: ciproXR (CFXR) and azathioprine (AZA). Gut 2008;57(Suppl 2):A374
   PubMedGoogle Scholar
• Walsh SL, Strain EC, Abreu ME, et al. Enadoline, a selective kappa opioid agonist: comparison with butorphanol and hydromorphone in humans. Psychopharmacology (Berl) 2001;157(2):151-62
   PubMed Web of Science ®Google Scholar
• Barber A, Bartoszyk GD, Bender HM, et al. A pharmacological profile of the novel, peripherally-selective kappa-opioid receptor agonist, EMD 61753. Br J Pharmacol 1994;113(4):1317-27
   PubMed Web of Science ®Google Scholar
• Jonker JW, Wagenaar E, van Deemter L, et al. Role of blood-brain barrier P-glycoprotein in limiting brain accumulation and sedative side-effects of asimadoline, a peripherally acting analgesic drug. Br J Pharmacol 1999;127(1):43-50
   PubMed Web of Science ®Google Scholar
• Szarka LA, Camilleri M, Burton D, et al. Efficacy of on-demand asimadoline, a peripheral K-opioid agonist, in females with irritable bowel syndrome. Clin Gastroenterol Hepatol 2007;5(11):1268-75
   PubMed Web of Science ®Google Scholar
• Mangel AW, Bornstein JD, Hamm LR, et al. Clinical trial: asimadoline in the treatment of patients with irritable bowel syndrome. Aliment Pharmacol Ther 2008;28(2):239-49
   PubMed Web of Science ®Google Scholar
• Mangel AW, Williams VS. Asimadoline in the treatment of irritable bowel syndrome. Expert Opin Investig Drugs 2010;19(10):1257-64
   PubMed Web of Science ®Google Scholar
• Tioga Pharmaceuticals. Study of asimadoline to treat diarrhea-predominant irritable bowel syndrome (D-IBS). Clinicaltrials.gov web site. Available from: http://clinicaltrials.gov/ct2/show/study/NCT01100684?term=asimadoline&rank=4 [Last accessed 19 November 2013]
   Google Scholar
• Wade PR, Palmer JM, McKenney S, et al. Modulation of gastrointestinal function by MuDelta, a mixed µ opioid receptor agonist/ µ opioid receptor antagonist. Br J Pharmacol 2012;167:1111-25
   PubMed Web of Science ®Google Scholar
• Dove LS, Lembo A, Randall CW, et al. Eluxadoline benefits patients with irritable bowel syndrome with diarrhea in a Phase II study. Gastroenterology 2013;145:329-38.e1
   PubMed Web of Science ®Google Scholar
• Lazard Capital Markets Annual Healthcare Conference. Furiex Pharmaceuticals. Available from: http://files.shareholder.com/downloads/ABEA-4H9PM 3/0x0x550458/a546b8d0-d614-4136-9514-3c960c74649f/Lazard%20Capital %20Markets%20Annual% 20Healthcare% 20Conference% 20Presentation [Last accessed 11 November 2013]
   Google Scholar
• EU Clinical trials register. A randomized, double-blind, placebo-controlled, Phase III study to evaluate the efficacy, safety, and tolerability of JNJ-27018966 in the treatment of patients with diarrhea-predominant irritable bowel syndrome. Available from: https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-001601-24
   Google Scholar
• Furiex pharmaceuticals: eluxadoline. Available from: http://www.furiex.com/pipeline/discoverydevelopment-pipeline/mu-delta/
   Google Scholar
• Brown P, Drossman DA, Wood A, et al. The tryptophan hydroxylase inhibitor LX1031 shows clinical benefit in patients with nonconstipating irritable bowel syndrome. Gastroenterology 2011;141(2):507-16
   PubMed Web of Science ®Google Scholar
• Camilleri M. LX-1031, a tryptophan 5-hydroxylase inhibitor that reduces 5-HT levels for the potential treatment of irritable bowel syndrome. IDrugs 2010;13(12):921-8
   PubMed Web of Science ®Google Scholar
• Lordal M, Navalesi G, Theodorsson E, et al. A novel tachykinin NK2 receptor antagonist prevents motility-stimulating effects of neurokinin a in small intestine. Br J Pharmacol 2001;134:215-23
   PubMed Web of Science ®Google Scholar
• Gerspacher M, La VL, Mah R, et al. Dual neurokinin NK(1)/ NK(2) antagonists: N-[(R,R)-(E)-1-arylmethyl-3-(2-oxo-azepan-3-yl)carbamoyl]allyl-Nmethyl-3,5-bis(trifluoromethyl)benzamides and 3-[N’-3,5-bis(trifluoromethyl)benzoyl-N-arylmethyl-N’-methylhydrazino]-N-[(R)-2-oxo-azepan-3-yl]propionamides. Bioorg Med Chem Lett 2001;11:3081-4
   PubMed Web of Science ®Google Scholar
• Tough IR, Lewis CA, Fozard J, et al. Dual and selective antagonism of neurokinin NK(1) and NK(2) receptor-mediated responses in human colon mucosa. Naunyn Schmiedebergs Arch Pharmacol 2003;367:104-8
   PubMed Web of Science ®Google Scholar
• Zakko S, Barton G, Weber E, et al. Randomised clinical trial: the clinical effects of a novel neurokinin receptor antagonist, DNK333, in women with diarrhoea-predominant irritable bowel syndrome. Aliment Pharmacol Ther 2011;33:1311-21
   PubMed Web of Science ®Google Scholar
• Frissora CL. A new look at irritable bowel syndrome (IBS): a neuroenteric disorder. Comp Ther 2002;28:222-31
   PubMedGoogle Scholar
• Leventer SM, Raudibaugh K, Frissora CL, et al. Clinical trial: dextofisopam in the treatment of patients with diarrhoea-predominant or alternating irritable bowel syndrome. Aliment Pharmacol Ther 2008;27:197-206
   PubMed Web of Science ®Google Scholar
• Jan F, Yavor S, Bochenek A, et al. Efficacy of ibodutant, a selective antagonist of neurokinin 2 receptors, in irritable bowel syndrome with diarrhoea (IBS-D): the results of a double-blind, randomised, placebo-controlled, parallel-group Phase II study (the IRIS-2). Nr. 520; Digestive Disease Week 2013
   Google Scholar
• 12-Week efficacy and safety study of ibodutant in women with irritable bowel syndrome with diarrhea (IBS-D) (IRIS-3). Available from: http://clinicaltrials.gov/show/NCT02107196
   Google Scholar
• Assimakopoulos SF, Scopa CD, Nikolopoulou VN, et al. Pleiotropic effects of bombesin and neurotensin on intestinal mucosa: not just trefoil peptides. World J Gastroenterol 2008;14(22):3602-3
   PubMed Web of Science ®Google Scholar
• Martinez V, Taché Y. Bombesin and the brain-gut axis. Peptides 2000;21(11):1617-25
   PubMed Web of Science ®Google Scholar
• A Phase II pilot study to assess ASP7147 in patients with diarrhea predominant irritable bowel syndrome (IBS-D). Available from: http://clinicaltrials.gov/ct2/results?term=seldar+pharma+inc
   Google Scholar
• Tradtrantip L, Namkung W, Verkman AS. Crofelemer, an antisecretory antidiarrheal proanthocyanidin oligomer extracted from Croton lechleri, targets two distinct intestinal chloride channels. Mol Pharmacol 2010;77:69-78
   PubMed Web of Science ®Google Scholar
• Holodniy M, Koch J, Mistal M, et al. A double-blind, placebo-controlled Phase II study to assess the safety and efficacy of orally administered SP-303 for the symptomatic treatment of diarrhea in patients with AIDS. Am J Gastroenterol 1999;94:3267-73
   PubMed Web of Science ®Google Scholar
• DiCesare D, Dupont HL, Mathewson JJ, et al. A double blind, randomized, placebo-controlled study of SP-303 (Provir) in the symptomatic treatment of acute diarrhea among travelers to Jamaica and Mexico. Am J Gastroenterol 2002;97:2585-8
   PubMed Web of Science ®Google Scholar
• Mangel AW, Chaturvedi P. Evaluation of crofelemer in the treatment of diarrhea-predominant irritable bowel syndrome patients. Digestion 2008;78:180-6
   PubMed Web of Science ®Google Scholar
• Camilleri M, Lasch K, Zhou W. Irritable bowel syndrome: methods, mechanisms, and pathophysiology. The confluence of increased permeability, inflammation, and pain in irritable bowel syndrome. Am J Physiol Gastrointest Liver Physiol 2012;303(7):G775-85
   PubMed Web of Science ®Google Scholar
• Basra S, Verne GN, Zhou Q. Randomized placebo controlled trial of glutamine for the treatment of diarrhea-predominant irritable bowel syndrome. Gastroenterology 2013;144(5 suppl 1):S160
   Web of Science ®Google Scholar
• Fukudo S, Kaneko H, Akiho H, et al. Evidence-based clinical practice guidelines for irritable bowel syndrome. J Gastroenterol 2015;50:11-30
   PubMed Web of Science ®Google Scholar